Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
received:
08
03
2024
accepted:
02
05
2024
revised:
01
05
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
aheadofprint
Résumé
Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1
Identifiants
pubmed: 38755421
doi: 10.1038/s41375-024-02278-8
pii: 10.1038/s41375-024-02278-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
pubmed: 32127639
pmcid: 7214240
doi: 10.1038/s41375-020-0776-2
Patel AB, O’Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin N Am. 2017;31:589–612.
doi: 10.1016/j.hoc.2017.04.007
Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.
pubmed: 33736651
pmcid: 7976694
doi: 10.1186/s13045-021-01055-9
Akard LP, Albitar M, Hill CE, Pinilla-Ibarz J. The “hit hard and hit early” approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer Network clinical practice guidelines for routine practice. Clin Adv Hematol Oncol. 2013;11:421–32.
Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15:323–34.
pubmed: 25971713
pmcid: 5141582
doi: 10.1016/j.clml.2015.03.006
Bosi GR, Fogliatto LM, Costa TEV, Grokoski KC, Pereira MP, Bugs N, et al. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials? Hematol Transfus Cell Ther. 2019;41:222–8.
pubmed: 31085148
pmcid: 6732531
doi: 10.1016/j.htct.2018.11.005
Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin N Am. 2011;25:981–95.
doi: 10.1016/j.hoc.2011.09.004
Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510–6.
pubmed: 23716543
pmcid: 3789454
doi: 10.3324/haematol.2012.080234
Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38:10–20.
pubmed: 24131888
doi: 10.1016/j.leukres.2013.09.011
Dhillon S. Olverembatinib: first approval. Drugs. 2022;82:469–75.
pubmed: 35195876
doi: 10.1007/s40265-022-01680-9
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–80.
pubmed: 11423618
doi: 10.1126/science.1062538
Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.
pubmed: 33096322
doi: 10.1016/j.leukres.2020.106458
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404.
pubmed: 29567798
pmcid: 6071555
doi: 10.1182/blood-2016-09-739086
Deininger MW, Apperley JF, Arthur CK, Chuah C, Hochhaus A, De Lavallade H, et al. Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) By baseline BCR-ABL1 level and baseline mutation status in the OPTIC Trial. Blood. 2021;138:307.
doi: 10.1182/blood-2021-145995
Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, et al. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018;59:1312–22.
pubmed: 28972430
doi: 10.1080/10428194.2017.1379076
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042–50.
pubmed: 34407543
pmcid: 9728404
doi: 10.1182/blood.2021012082
Molica M, Scalzulli E, Colafigli G, Foa R, Breccia M. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol. 2019;10:2040620719826444.
pubmed: 30854182
pmcid: 6399752
doi: 10.1177/2040620719826444
Iclusig (Ponatinib) [package insert]. Cambridge MTPCL.
Jabbour E, Kantarjian H, O’Brien S, Shan J, Quintas-Cardama A, Faderl S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541–6.
pubmed: 21803854
pmcid: 3291489
doi: 10.1182/blood-2011-04-348110
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29:1634–42.
pubmed: 21422420
doi: 10.1200/JCO.2010.32.0598
Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024;38:475–81.
pubmed: 38287132
pmcid: 10912029
doi: 10.1038/s41375-024-02159-0
Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120–35.
pubmed: 30137981
doi: 10.1021/acs.jmedchem.8b01040
Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7.
pubmed: 28329763
doi: 10.1038/nature21702
Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031–41.
pubmed: 34407542
pmcid: 9728405
doi: 10.1182/blood.2020009984
Mauro MJ, Hughes TP, Kim D-W, Réa D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-Year phase 1 safety and efficacy results. Leukemia. 2023;37:1048–59.
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–26.
pubmed: 31826340
pmcid: 7724923
doi: 10.1056/NEJMoa1902328
Novartis Pharmaceuticals Corporation. NDA/BLA Multi-disciplinary Review and Evaluation {NDA 215358} SCEMBLIX (asciminib). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000MultidisciplineR.pdf . Accessed 29 Apr 2024.
Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB. Exposure-efficacy analysis of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther. 2022;112:1040–50.
Scemblix (asciminib) [package insert]. East Hanover, NJ; Novartis Pharmaceutical Corporation. 2023.
Hughes TP, Cortes JE, Réa D, Mauro MJ, Hochhaus A, Kim D-W, et al. Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial. Presented at: EHA2022 Congress; June 9-17, 2022; Vienna, Austria, and Online. Poster P704.
Scemblix (asciminib) [prescribing information]. Macquarie Park N, Australia; Novartis Pharmaceuticals Australia Pty Limited; 2022.
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.
pubmed: 19884523
pmcid: 4979100
doi: 10.1200/JCO.2009.25.0779
Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823–31.
pubmed: 26088952
doi: 10.1038/leu.2015.152
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.
pubmed: 17151364
doi: 10.1056/NEJMoa062867
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.
pubmed: 24180494
doi: 10.1056/NEJMoa1306494
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.
pubmed: 28804124
pmcid: 5668495
doi: 10.1038/leu.2017.253
Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500.
pubmed: 24311723
pmcid: 4190618
doi: 10.1182/blood-2013-06-511592
Cortes J, Quintas-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011;117:1113–22.
pubmed: 20960522
doi: 10.1002/cncr.25527
Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415–23.
pubmed: 24297946
doi: 10.1200/JCO.2013.49.9020
Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O’Brien S, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88:1024–9.
pubmed: 23913852
doi: 10.1002/ajh.23560
Garcia-Horton A, Lipton JH. Treatment outcomes in chronic myeloid leukemia: does one size fit all? J Natl Compr Canc Netw. 2020;18:1421–8.
pubmed: 33022650
doi: 10.6004/jnccn.2020.7627
Etienne G, Dulucq S, Nicolini FE, Morrisset S, Fort MP, Schmitt A, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 2014;99:458–64.
pubmed: 24362549
pmcid: 3943308
doi: 10.3324/haematol.2013.095158
Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617–26.
Santoro M, Mancuso S, Accurso V, Di Lisi D, Novo G, Siragusa S. Cardiovascular issues in tyrosine kinase inhibitors treatments for chronic myeloid leukemia: a review. Front Physiol. 2021;12:675811.
pubmed: 34290617
pmcid: 8287514
doi: 10.3389/fphys.2021.675811
Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS). Cancers. 2020;12:826.
pubmed: 32235443
pmcid: 7226142
doi: 10.3390/cancers12040826
Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293–303.
pubmed: 28831263
pmcid: 5552150
doi: 10.2147/VHRM.S108874
Gleevec (imatinib) [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation. 2024.
Tasigna (nilotinib) [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation. 2024.
Sprycel (dasatinib) [package insert]. Princeton, NJ; Bristol-Myers Squibb Company. 2023.
Bosulif (bosutinib) [package insert]. New York, NY; Pfizer Labs. 2023.
Singh AP, Glennon MS, Umbarkar P, Gupte M, Galindo CL, Zhang Q, et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res. 2019;115:966–77.
pubmed: 30629146
pmcid: 6452321
doi: 10.1093/cvr/cvz006
Cheng S, Jin P, Li H, Pei D, Shu X. Evaluation of CML TKI induced cardiovascular toxicity and development of potential rescue strategies in a zebrafish model. Front Pharmacol. 2021;12:740529.
pubmed: 34733159
pmcid: 8558359
doi: 10.3389/fphar.2021.740529
Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong ASM, et al. Excellent early and major molecular responses observed with asciminib treatment for CP-CML: results from the ALLG CML13 Ascend-CML study. Presentation at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA, & Online. Abstract P704.
Réa D, Hochhaus A, Mauro MJ, Minami Y, Lomaia E, Voloshin S, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after =/>2 prior tyrosine kinase inhibitors: wk 96 update. Presented at: EHA2022 Congress; June 9-17, 2022; Vienna, Austria, and Online. Abstract S155.
Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after >/=2 prior TKIs. Blood. 2021;138:2031–41.
Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–71.
pubmed: 27121688
pmcid: 4991363
doi: 10.1038/leu.2016.104
Rea D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol. 2015;94:S149–58.
pubmed: 25814081
doi: 10.1007/s00277-015-2318-y
Luna A, Perez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuno C, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022;101:2263–70.
pubmed: 35997804
pmcid: 9463214
doi: 10.1007/s00277-022-04932-6